<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114257</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02657</org_study_id>
    <secondary_id>MDA-2004-0674</secondary_id>
    <secondary_id>NCI-5563</secondary_id>
    <secondary_id>CDR0000433040</secondary_id>
    <nct_id>NCT00114257</nct_id>
  </id_info>
  <brief_title>Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders</brief_title>
  <official_title>A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of decitabine and FR901228 in&#xD;
      treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or&#xD;
      myeloproliferative disorders. Drugs used in chemotherapy, such as decitabine and FR901228,&#xD;
      work in different ways to stop the growth of cancer cells, either by killing the cells or by&#xD;
      stopping them from dividing. FR901228 may also stop the growth of cancer cells by blocking&#xD;
      some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving&#xD;
      decitabine together with FR901228 may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and recommended phase II dose of decitabine and&#xD;
      FR901228 (depsipeptide) in patients with relapsed or refractory leukemia, myelodysplastic&#xD;
      syndromes, or myeloproliferative disease.&#xD;
&#xD;
      II. Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide)&#xD;
      IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for&#xD;
      at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      experiencing complete remission for 1 year are removed from the study.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity at 6 weeks after each course</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete and partial response at 6 weeks after each course</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.&#xD;
Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
                    -  Previously untreated patients &gt; 60 years of age who are not eligible for&#xD;
                       front-line therapy are eligible for this study&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  Documented hematologic resistance to imatinib mesylate OR no cytogenetic&#xD;
                       response after 12 months of prior treatment with imatinib mesylate&#xD;
&#xD;
                    -  Philadelphia chromosome-negative CML allowed provided disease is resistant&#xD;
                       to standard therapy (e.g., hydroxyurea) OR disease progressed (blasts &gt; 5%&#xD;
                       and platelet count &lt; 100,000/mm^3) during standard therapy&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
                    -  International Prognostic Scoring System risk category ≥ intermediate-1&#xD;
&#xD;
                    -  Patients who are not eligible for front-line therapy are eligible for this&#xD;
                       study&#xD;
&#xD;
               -  Myeloproliferative disease&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Failed or progressed during ≥ 1 prior fludarabine-based therapy AND&#xD;
                       alemtuzmab&#xD;
&#xD;
               -  Acute promyelocytic leukemia&#xD;
&#xD;
                    -  Progressed after prior treatment with standard chemotherapy, tretinoin, and&#xD;
                       arsenic trioxide&#xD;
&#xD;
               -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Resistant to standard therapy (e.g., hydroxyurea) OR disease progressed&#xD;
                       (blasts &gt; 5% and platelet count &lt; 100,000/mm^3) during standard therapy&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  No known brain or meningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled dysrhythmias&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No left ventricular hypertrophy by EKG&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or&#xD;
             ventricular fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to study drugs&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
             unless there is evidence of rapidly progressive disease&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent agents that cause QTc prolongation&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
&#xD;
          -  No concurrent hydrochlorothiazide&#xD;
&#xD;
               -  Concurrent potassium-conserving combinations (e.g., Maxide® or Dyazide®) or other&#xD;
                  antihypertensive agents allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Issa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>June 13, 2005</study_first_submitted>
  <study_first_submitted_qc>June 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2005</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

